Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 18/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407896 | 0.92 | NR1H2 (0.57) | NR1H2NR1H3PTPN2PTPN1PTPRB | |
| SCHEMBL1407358 | 0.88 | NR1H2 (0.60) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1407267 | 0.87 | NR1H2 (0.73) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1407116 | 0.85 | NR1H2 (0.59) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1407885 | 0.84 | NR1H2 (0.62) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1407639 | 0.84 | NR1H2 (0.57) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1407659 | 0.83 | NR1H2 (0.52) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1414670 | 0.83 | NR1H2 (0.60) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1408103 | 0.82 | NR1H2 (0.67) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL1407748 | 0.82 | NR1H2 (0.67) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |